Overview

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2028-09-25
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of apatinib combined with adebrelizumab and EC in the first-line treatment of extensive small cell lung cancer
Phase:
PHASE2
Details
Lead Sponsor:
Fujian Cancer Hospital
Treatments:
apatinib
Carboplatin
Etoposide